Pages

Saturday 29 August 2020

How Amazon’s new health tracker will use AI to monitor your tone of voice

Amazon may not have unlocked the secret to happiness. But with the announcement of a new voice monitoring tool called Tone, the company promises that it knows what happiness sounds like. And that—with a new gadget and a little tracking—you, too, can sound happy.



By Nicolás Rivero
Reporter
A silver Amazon Halo wristband sits next to a smartphone displaying the sleek Halo app
Humans have been wrestling with how to define happiness for eons. Can Amazon’s AI crack that nut?
Tone will be a feature on Amazon’s new wearable health tracker, dubbed Halo. Users can opt in to let it sample snippets of their speech throughout the day, or turn it on for up to 30 minutes at a time to get a detailed report on how they sounded in a particular conversation. Powered by AI algorithms designed to detect the “positivity” and “energy” in human voices, the tool purports to offer users feedback on their tone so they can improve their communication skills and relationships.
Of course, it’s hard to define fuzzy traits like positivity—and it’s an even more Herculean task to train an AI model to objectively quantify and measure them. In a blog post, Amazon simply says that “positivity” measures how happy or sad a voice sounds. But humanity (and the field of positive psychology) have been wrestling with how to define happiness for eons.
“It’s hard for me to imagine that there could be a single objective measure,” said Jim Allen, an associate professor of psychology at the State University of New York at Geneseo who writes and teaches about the psychology of happiness. Our perception of what a happy voice sounds like, he notes, varies depending on culture, gender, ethnicity, and other personal factors.
An Amazon spokesperson said that the developers had accounted for these differences by drawing on vocal samples from tens of thousands of voices from across US regions and demographic groups. A team of Amazon employees then listened to the recordings and rated the voices as happy or sad to determine “positivity” and tired or excited to measure “energy.” The model associated those emotional ratings with vocal qualities like pitch, intensity, tempo, and rhythm, which the AI uses to label users’ speech.
Training sets, however, are highly susceptible to bias from the humans who build them, as researchers have extensively documented in fields like facial recognition. That makes vetting the data, and the people who label it, very important. Amazon declined to offer any detail about the demographic breakdown of its vocal samples, or the team whose perceptions of positivity and energy form the basis for the model. “Throughout product development, we’ve focused on ensuring the data we use to train and evaluate our models accounts for all demographic groups,” a spokesperson said in an email.
In particular contexts, Allen said some version of a tool like Tone could work well. “In the hands of a skilled counselor giving feedback to a client about how they come across to other people, it could be really helpful,” he said. But, he noted, constantly monitoring yourself for signs of happiness—or worse, projecting a positivity you do not feel—has been shown to make people less happy.
Pattie Maes, an MIT professor who studies wearable technology designed to enhance people’s lives, pointed out that the AI would be more likely to return meaningful results if it didn’t try to treat happiness as a universal truth. “People have different speaking styles,” she said in an email. “I believe a personalized AI model trained on an individual’s own data would perform better.” (While Tone learns to pick out a user’s voice in a conversation, it does not calibrate its ratings to that user’s emotional baseline.)
But these approaches to boosting the model’s validity are not compatible with mass consumer tech. In its announcement blog post, Amazon medical officer Maulik Majmudar describes a gadget that comes out of a box ready to coax users into better communication. He writes about the ease with which his colleagues can turn on Tone and rehearse for a big presentation at work. Majmudar says he switches the system on before talking to his children, to make sure he’s not taking work stress out on his family.
It’s an intriguing vision for an AI-enabled future. But it might not be the one we live in right now.

AI funding boost aims to speed up cancer diagnoses

Artificial intelligence capable of spotting deadly diseases like cancer is to receive a £50 million funding boost in a bid to speed up diagnosis times.
Jamie Harris, PA Science Technology Reporter
The extra cash is being awarded to three specialist centres based in Coventry, Leeds and London, delivering digital upgrades to pathology and imaging services across an additional 38 NHS trusts, the Department of Health and Social Care (DoH) said.
It is hoped the technology will improve outcomes for millions of patients, providing a more accurate diagnosis and freeing up NHS staff time, as part of a Government commitment to detect three quarters of cancers at an early stage by 2028.
Health Secretary Matt Hancock said: “Technology is a force for good in our fight against the deadliest diseases – it can transform and save lives through faster diagnosis, free up clinicians to spend time with their patients and make every pound in the NHS go further.

Health Secretary Matt Hancock said the investment will ‘make every pound in the NHS go further’ (Jonathan Brady/PA)
Health Secretary Matt Hancock said the investment will ‘make every pound in the NHS go further’ (Jonathan Brady/PA)

“I am determined we do all we can to save lives by spotting cancer sooner.
“Bringing the benefits of artificial intelligence to the front line of our health service with this funding is another step in that mission.
“We can support doctors to improve the care we provide and make Britain a world-leader in this field.
“The NHS is open and I urge anyone who suspects they have symptoms to book an appointment with their GP as soon as possible to benefit from our excellent diagnostics and treatments.”
The Government said the investment will support its long-term response to Covid-19, allowing centres to work with British businesses and thereby support the economic recovery.
The DoH said that since the beginning of the coronavirus pandemic, more than 92% of urgent cancer referrals have been investigated within two weeks and 85,000 people have started treatment.
Darren Treanor, a consultant pathologist at Leeds Teaching Hospitals NHS Trust and director of one of the three centres, said: “This investment will allow us to use digital pathology to diagnose cancer at 21 NHS trusts in the North, serving a population of six million people.
“We will also build a national network spanning another 25 hospitals in England, allowing doctors to get expert second opinions in rare cancers, such as childhood tumours, more rapidly.”
https://uk.finance.yahoo.com/news/ai-funding-boost-aims-speed-230100224.html


Monday 24 August 2020

Six of the most promising treatments for Covid-19 so far

While a cure-all drug or therapy is a long way off, there have been some breakthroughs






Belgian pharmacist with Dexamethasone

 A Belgian pharmacist with a container of Dexamethasone, a cheap and standard treatment for the sickest Covid patients. Photograph: Yves Herman/Reuters


Many different drugs and therapies are being trialled and used on patients with Covid-19. There are some positive results, which may be beginning to bring the hospital death toll down, but there is still a long way to go towards something that will cure all comers. These are some of the most promising.

1. Dexamethasone

This is the success story – a very cheap drug, in plentiful supply around the world – that has been shown to save lives. The low-dose steroid was responsible for the survival of one in eight patients on ventilators during the Oxford University-based Recovery trial. The results were announced in mid-June and the steroid is now standard treatment for the sickest patients. The data is reliable because it comes from the biggest randomised trial of Covid-19 treatments in the world, involving almost all hospitals in the UK. Dexamethasone has been around for 60 years, so is out of patent and cheap.

2. Convalescent blood plasma

This is plasma containing antibodies to the virus collected from people who have recovered from Covid-19. Donald Trump has become an enthusiast, as the US presidential election campaign picks up, announcing emergency authorisation for the treatment, which he claimed could prevent 35% of deaths. Although convalescent plasma has been successfully used to treat other diseases, most experts still say there is insufficient evidence from trials as to how well it works and on which patients. NHS Blood and Transplant is appealing for Covid-19 survivors to donate their plasma for trials that might benefit patients.

3. Remdesivir

The drug has been authorised for emergency use in the US, India and Singapore and approved in the European Union, Japan and Australia for use on people with severe symptoms. It’s an expensive drug, made by the US company Gilead Sciences, originally for hepatitis C, which it was ineffective on. It was then repurposed for Ebola. In Covid-19, it appears to shorten the length of an average hospital stay from 15 to 11 days, but it is not clear whether it has a dramatic effect on reducing deaths.

4. Tocilizumab

A number of anti-inflammatory treatments are being tested to see if they can help. The coronavirus attacks the immune system, which leads to inflammation. Tocilizumab, an antibody normally used to treat rheumatoid arthritis, is given by injection to block the inflammatory protein IL-6. Patients given the drug during the serious Covid-19 outbreak in Italy in March appeared to benefit and were less likely to end up on a ventilator or die. But the numbers were relatively small and this was an observational study, not a randomised trial set up to judge the outcomes of people with and without the drug. The Recovery trial is also investigating Tocilizumab.

5. Blood pressure pills

Scientists think people on medication because of their blood pressure would be well advised to stay on it. A paper from the University of East Anglia found that the risk of critical illness or death from Covid for people with high blood pressure was found to be significantly lower if they were taking angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). That does not mean those drugs would be helpful to anyone with coronavirus infection who does not suffer from high blood pressure.

6. Inhaled interferon beta

A small study from scientists at Southampton University suggests that an inhaler containing the drug interferon beta, used to treat multiple sclerosis, could be effective. The three academics behind it, who formed a spin-off company for their product in 2004, became paper millionaires when they announced the results of their trial on Covid-19 patients in July. The trial involved just 101 patients at 9 hospitals. Those inhaling the drug left hospital sooner and were more likely to recover, but the data was not published in full. Larger trials are needed.
“There is a big difference between encouraging early results and definitive evidence that transforms clinical practice,” commented Martin Landray, professor of medicine and epidemiology at Oxford University and one of the leaders of the Recovery trial at the time.


Covid vaccine tracker: when will we have a coronavirus vaccine?

More than 170 teams of researchers are racing to develop a safe and effective vaccine. Here is their progress


Pre-clinical
vaccines not yet in human trials 138

Phase 1
vaccines in small-scale safety trials 25

Phase 2
vaccines in expanded safety trials 15

Phase 3
vaccines in large-scale efficacy trials 7

Approved
vaccines approved for general use 0

Source: WHO. Last updated 17 Aug 2020


Researchers around the world are racing to develop a vaccine against Covid-19, with more than 170 candidate vaccines now tracked by the World Health Organization (WHO).

Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within 12 to 18 months.

Vaccines mimic the virus – or part of the virus – they protect against, stimulating the immune system to develop antibodies. They must follow higher safety standards than other drugs because they are given to millions of healthy people.

Recent vaccine news

Russian health authorities have approved a coronavirus vaccine which has yet to complete clinical trials. 2 weeks ago

How are vaccines tested?

In the pre-clinical stage of testing, researchers give the vaccine to animals to see if it triggers an immune response.
In phase 1 of clinical testing, the vaccine is given to a small group of people to determine whether it is safe and to learn more about the immune response it provokes.
In phase 2, the vaccine is given to hundreds of people so scientists can learn more about its safety and correct dosage.
In phase 3, the vaccine is given to thousands of people to confirm its safety – including rare side effects – and effectiveness. These trials involve a control group which is given a placebo.

Vaccines in clinical trials

Phase in progress

Phase completed

University of Oxford/AstraZeneca
The University of Oxford vaccine is delivered via a chimpanzee virus, called the vaccine vector. The vector contains the genetic code of the protein spikes found on the coronavirus and triggers a strong immune response in the human body. The vaccine is in a combined phase 2/3 trial in the UK and has recently gone into phase 3 trials in South Africa and Brazil.
BioNTech/Fosun Pharma/Pfizer
Moderna/NIAID
American biotech company Moderna is developing a vaccine candidate using messenger RNA (or mRNA for short) to trick the body into producing viral proteins itself. No mRNA vaccine has ever been approved for an infectious disease, and Moderna has never brought a product to market. But proponents of the vaccine say it could be easier to mass produce than traditional vaccines.
Sinovac
Chinese company Sinovac is developing a vaccine based on inactivated Covid-19 particles. The vaccine has shown a promising safety profile in the early stages of testing and is now moving into Phase 3 trials in Brazil.
Beijing Institute of Biological Products/Sinopharm
Wuhan Institute of Biological Products/Sinopharm
CanSino Biologics Inc./Beijing Institute of Biotechnology
Novavax
Arcturus/Duke-NUS
Cadila Healthcare Limited
Osaka University/ AnGes/ Takara Bio
Janssen Pharmaceutical Companies
Kentucky Bioprocessing, Inc
Bharat Biotech
Inovio Pharmaceuticals/ International Vaccine Institute
Institute of Medical Biology, Chinese Academy of Medical Sciences
Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences
Genexine Consortium
Medicago Inc.
Vaxine Pty Ltd/Medytox
University of Queensland/CSL/Seqirus
Medigen Vaccine Biologics Corporation/NIAID/Dynavax
People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.
Curevac
Imperial College London
Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme
Clover Biopharmaceuticals Inc./GSK/Dynavax
ReiThera/LEUKOCARE/Univercells
Gamaleya Research Institute
University of Melbourne/Murdoch Children’s Research Institute
The Murdoch Children’s Research Institute in Australia is conducting a phase 3 trial using a nearly 100-year-old tuberculosis vaccine. The vaccine is not thought to protect directly against Covid-19 but might boost the body’s non-specific immune response.
Source: WHO. Last updated 17 Aug